NovaBay Pharmaceuticals Plan of Compliance Accepted by NYSE
July 01 2019 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc.
(NYSE American: NBY), a biopharmaceutical company focusing on
commercializing Avenova® for the domestic eye care market,
announces that the New York Stock Exchange (NYSE) has accepted the
Company’s plan to regain compliance with the NYSE American’s
continued listing standards. As previously disclosed, the NYSE
notified the Company on April 12, 2019 and May 16, 2019 that it was
out of compliance with Exchange listing requirements.
Based upon a review of the compliance plan and information
submitted on May 11, 2019 by NovaBay, the Exchange determined that
the Company made a reasonable demonstration of its ability to make
substantial progress toward regaining compliance by October 12,
2020.
“We are pleased that our compliance plan has been accepted by
the exchange,” said Justin Hall, NovaBay’s President and CEO. “We
have successfully completed our two near-term strategies: the
launch of Avenova® Direct on Amazon and our cost
reduction plan. We are excited by our new forward momentum.”
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, NEUTROPHASE® for wound care
market, and CELLERX® for the aesthetic dermatology market. The
Aganocide compounds, still under development, have target
applications in the dermatology and urology markets.
Forward-Looking Statements
This release contains forward-looking statements that are based
upon management’s current expectations, assumptions, estimates,
projections and beliefs. These statements include, but are not
limited to, statements regarding our NYSE American listing status,
our future momentum, online sales and generally the company’s
expected future financial results. These statements involve known
and unknown risks, uncertainties and other factors that may cause
actual results or achievements to be materially different and
adverse from those expressed in or implied by the forward-looking
statements. Factors that might cause or contribute to such
differences include, but are not limited to, risks and
uncertainties relating to our ability to remain a publicly listed
company, maintain the support of our majority shareholders, and
ability to adhere to our approved NYSE compliance plan. Other risks
relating to NovaBay’s business, including risks that could cause
results to differ materially from those projected in the
forward-looking statements in this press release, are detailed in
NovaBay’s latest Form 10-Q/K filings with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay informed on NovaBay’s progress: Like
us on Facebook Follow us on Twitter
Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing Information For NovaBay Avenova
purchasing information: Please call 800-890-0329 or email
sales@avenova.com www.Avenova.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190701005191/en/
NovaBay Contact Justin Hall President and Chief Executive
Officer 510-899-8800 jhall@novabay.com
Investor Contact LHA Investor Relations Jody Cain
310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024